|
1
|
Kim YB and Suh CO: Evolution of radiotherapy: High-precision radiotherapy. J Korean Med Assoc. 51:604–611. 2008. View Article : Google Scholar
|
|
2
|
Gunderson LL and Tepper JE: Clinical radiation oncology. Elsevier Health Sciences; 2015
|
|
3
|
Yang XD, Xu XH, Zhang SY, Wu Y, Xing CG, Ru G, Xu HT and Cao JP: Role of miR-100 in the radioresistance of colorectal cancer cells. Am J Cancer Res. 5:545–559. 2015.PubMed/NCBI
|
|
4
|
Jin H, Gao S, Guo H, Ren S, Ji F, Liu Z and Chen X: Re-sensitization of radiation resistant colorectal cancer cells to radiation through inhibition of AMPK pathway. Oncol Lett. 11:3197–3201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee J, Kwon J, Kim D, Park M, Kim K, Bae I, Kim H, Kong J, Kim Y, Shin U and Kim E: Gene expression profiles associated with radio-responsiveness in locally advanced rectal cancer. Biology (Basel). 10:5002021.PubMed/NCBI
|
|
6
|
Austin C, Lo G, Nandha K, Meleagros L and Bloom S: Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract. J Mol Endocrinol. 14:157–169. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL Jr, Feighner SD, Nunes CN, et al: Identification of receptors for neuromedin U and its role in feeding. Nature. 406:70–74. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martinez VG and O'Driscoll L: Neuromedin U: A multifunctional neuropeptide with pleiotropic roles. Clin Chem. 61:471–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shan L, Qiao X, Crona JH, Behan J, Wang S, Laz T, Bayne M, Gustafson EL, Monsma FJ Jr and Hedrick JA: Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J Biol Chem. 275:39482–39486. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brighton PJ, Szekeres PG and Willars GB: Neuromedin U and its receptors: Structure, function, and physiological roles. Pharmacol Rev. 56:231–248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Przygodzka P, Soboska K, Sochacka E and Boncela J: Neuromedin U: A small peptide in the big world of cancer. Cancers (Basel). 11:13122019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Q, Han L, Ruan S, Shen S, Cao Q, Cai X, Yan Y, Peng B and Hua Y: The prognostic value of neuromedin U in patients with hepatocellular carcinoma. BMC Cancer. 20:952020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan J, Li S, Chi P, Xu Z, Lu X and Huang Y: Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. Oncol Rep. 28:179–185. 2012.PubMed/NCBI
|
|
14
|
Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell. 124:267–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sturbaut M, Bailly F, Coevoet M, Sileo P, Pugniere M, Liberelle M, Magnez R, Thuru X, Chartier-Harlin MC, Melnyk P, et al: Discovery of a cryptic site at the interface 2 of TEAD-towards a new family of YAP/TAZ-TEAD inhibitors. Eur J Med Chem. 226:1138352021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu C, Huang W and Lei Q: Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol. 2:247–256. 2011.PubMed/NCBI
|
|
18
|
Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim MH and Kim J: Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci. 74:1457–1474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, Nahlé Z and Kenney AM: Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 31:1923–1937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Wang Y, Zhou D, Wang K, Wang X, Wang X, Jiang Y, Zhao M, Yu R and Zhou X: Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 40:4580–4591. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA and Crane CH: Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 109:1750–1755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kremser C, Trieb T, Rudisch A, Judmaier W and de Vries A: Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: Sequence implementation and data analysis. J Magn Reson Imaging. 26:662–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Passiglia F, Bronte G, Castiglia M, Listì A, Calò V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V and Russo A: Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? Expert Opin Biol Ther. 15:1553–1566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW and Friess H: Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett. 277:72–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, et al: The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harten SK, Esteban MA, Shukla D, Ashcroft M and Maxwell PH: Inactivation of the von Hippel-Lindau tumour suppressor gene induces neuromedin U expression in renal cancer cells. Mol Cancer. 10:892011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin TY, Wu FJ, Chang CL, Li Z and Luo CW: NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling. Oncotarget. 7:10228–10242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M and Theodorescu D: Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene. 26:765–773. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martinez VG, Crown J, Porter RK and O'Driscoll L: Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. Int J Cancer. 140:2771–2784. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang D, Zhang X, Li Z, Xu F, Tang C and Chen H: Neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma. PeerJ. 9:e115122021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR, Kalota A, Choi JK and Gewirtz AM: Neuromedin U: A Myb-regulated autocrine growth factor for human myeloid leukemias. Blood. 104:1833–1840. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Przygodzka P, Papiewska-Pajak I, Bogusz H, Kryczka J, Sobierajska K, Kowalska MA and Boncela J: Neuromedin U is upregulated by Snail at early stages of EMT in HT29 colon cancer cells. Biochim Biophys Acta. 1860:2445–2453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Przygodzka P, Sochacka E, Soboska K, Pacholczyk M, Papiewska-Pająk I, Przygodzki T, Płociński P, Ballet S, De Prins A and Boncela J: Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor. J Exp Clin Cancer Res. 40:2832021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P and Leduc R: The signaling signature of the neurotensin type 1 receptor with endogenous ligands. Eur J Pharmacol. 805:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo Y, Luo J, Zou H, Liu C, Deng L and Li P: Context-dependent transcriptional regulations of YAP/TAZ in cancer. Cancer Lett. 527:164–173. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, et al: YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 35:1541–1553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tsujiura M, Mazack V, Sudol M, Kaspar HG, Nash J, Carey DJ and Gogoi R: Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One. 9:e1009742014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Akervall J, Nandalur S, Zhang J, Qian CN, Goldstein N, Gyllerup P, Gardinger Y, Alm J, Lorenc K, Nilsson K, et al: A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 50:570–581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vigneron AM, Ludwig RL and Vousden KH: Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev. 24:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee WY, Kuo CC, Lin BX, Cheng CH, Chen KC and Lin CW: Podocalyxin-like protein 1 regulates TAZ signaling and stemness properties in colon cancer. Int J Mol Sci. 18:20472017. View Article : Google Scholar : PubMed/NCBI
|
